My Reports
RGCIRC, Niti Bagh
Neuroblastoma Treatment in Delhi
Overview
Neuroblastoma is a rare and complex childhood cancer that requires highly specialised, risk-adapted care. At RGCIRC (Rajiv Gandhi Cancer Institute & Research Centre), children diagnosed with neuroblastoma receive comprehensive treatment guided by detailed tumour biology assessment, accurate staging, and coordinated multidisciplinary planning led by experienced paediatric oncologists. The treatment is based on key factors such as the child’s age, extent of disease, genetic characteristics of the tumour, and the child’s overall health. This approach ensures that children with low- and intermediate-risk neuroblastoma receive effective yet appropriately balanced therapy, while those with high-risk disease are managed through carefully planned, multi-modality treatment pathways.
Understanding Neuroblastoma
Neuroblastoma is a type of cancer that develops from immature nerve cells, known as neuroblasts, which are involved in the formation of the body’s sympathetic nervous system. These cells are most active during early foetal development, which explains why neuroblastoma is seen almost exclusively in infants and young children, with the majority of cases diagnosed before the age of six.
The tumour most commonly originates in the adrenal glands, located above the kidneys, but it can also arise anywhere along the sympathetic nerve chain. As a result, neuroblastoma may develop in the abdomen, chest, neck, or near the spine. The location of the tumour often influences the symptoms a child experiences and the complexity of treatment.
One of the unique features of neuroblastoma is its highly variable behaviour. In some children, particularly those with low-risk disease, the tumour may grow slowly, mature into a benign form, or even regress spontaneously without aggressive treatment. In contrast, other cases can be fast-growing and spread to distant parts of the body, requiring intensive, multi-stage therapy. Because of this unpredictability, accurate diagnosis and risk assessment are critical in determining the most appropriate treatment approach.
Who is at Risk of Neuroblastoma?
Neuroblastoma primarily affects infants and young children, making age the most significant risk factor. Most cases are diagnosed in children under six years of age, with a substantial number identified in infancy. The condition is uncommon in older children and rare in adolescents and adults.
In the majority of cases, neuroblastoma occurs sporadically, meaning there is no clear inherited cause or identifiable trigger. These cancers arise from developmental changes in nerve cells that occur before birth, and parents should understand that nothing they did or did not do causes the disease.
Neuroblastoma may be rarely associated with inherited genetic changes. Certain tumour biology features, such as specific genetic alterations within cancer cells, can influence how the disease behaves and how it responds to treatment. These factors are assessed after diagnosis and help doctors classify the disease into different risk groups, ensuring that each child receives the most appropriate level of care.
Signs and Symptoms of Neuroblastoma
The symptoms of neuroblastoma vary depending on the location of the tumour, its size, and whether the disease has spread. In many children, symptoms may appear gradually and can initially resemble common childhood conditions, making careful observation important.
Common signs and symptoms may include:
- Abdominal mass or swelling, often noticed by parents during routine care; the abdomen may feel firm or appear enlarged, with or without pain
- Fever, unexplained weight loss, weakness, or reduced appetite, reflecting the body’s response to the disease
- Bone pain, limping, or difficulty walking, which can occur if the cancer has spread to the bones or bone marrow
- High blood pressure, excessive sweating, or flushing, caused by hormone-like substances released by the tumour
- Neurological symptoms, such as weakness, changes in movement, or signs of spinal compression, if the tumour affects nerves or the spine
When to See a Specialist
While some symptoms of neuroblastoma may resemble common childhood illnesses, certain warning signs require prompt evaluation by a specialist. Early referral to a paediatric oncology centre is essential, as timely diagnosis allows for accurate risk assessment and appropriate treatment planning.
Parents and caregivers should seek specialist care if a child shows:
- A persistent or enlarging abdominal lump, especially if it is firm or associated with discomfort
- Ongoing bone pain, limping, or reduced mobility, particularly when symptoms worsen or affect daily activities
- Unexplained weight loss, prolonged fever, or increasing weakness that does not improve with routine care
- Signs of high blood pressure, such as headaches, excessive sweating, or flushing
- Neurological changes, including weakness, changes in walking, or symptoms suggestive of spinal compression
Prompt evaluation by experienced specialists helps confirm the diagnosis, assess disease extent, and initiate treatment without unnecessary delay, which can significantly influence outcomes.
How Neuroblastoma is Diagnosed at RGCIRC
At RGCIRC, the diagnosis of neuroblastoma follows internationally accepted criteria and is carried out through a structured, stepwise evaluation. Accurate diagnosis is essential not only to confirm the disease but also to determine risk category and guide treatment planning.
The diagnostic evaluation typically includes:
- Detailed clinical examination and medical history, focusing on the child’s symptoms, duration of illness, growth patterns, and physical findings such as abdominal masses or neurological changes
- Imaging studies, including ultrasound, CT scan, or MRI, to identify the tumour, assess its size and location, and evaluate involvement of surrounding organs or structures
- Functional imaging, using specialised scans to detect tumour spread, evaluate disease activity, and assess response to treatment when required
- Blood and urine tests, performed to measure specific substances released by neuroblastoma cells, which support diagnosis and monitoring
- Tumour biopsy, where a tissue sample is examined under a microscope to confirm neuroblastoma and assess tumour characteristics
- Bone marrow examination, carried out in selected cases to determine whether the disease has spread to the bone marrow
Once the diagnosis is established, additional laboratory and molecular tests are performed to evaluate tumour biology. These findings play a key role in staging the disease, assessing prognosis, and developing a personalised, risk-adapted treatment plan for each child at RGCIRC.
Treatment Options for Neuroblastoma at RGCIRC, Delhi
Treatment for neuroblastoma at RGCIRC follows a structured, risk-adapted approach, guided by the child’s age, stage of disease, tumour biology, and response to therapy. Each treatment plan is developed through multidisciplinary discussions involving paediatric oncologists, surgeons, radiation specialists, transplant teams, and supportive care services to ensure coordinated and child-focused care. Treatment options include:
Low-risk neuroblastoma
- Surgical management is the primary treatment for many children with low-risk disease. Surgery is carefully planned to remove the tumour while preserving surrounding organs and nerve structures, which is especially important in very young children.
- Active observation may be recommended for selected asymptomatic children, particularly when the tumour shows favourable biological behaviour. These children are closely monitored through regular imaging and clinical follow-up to ensure timely intervention if needed.
- Low-dose chemotherapy is used when symptoms are present or when complete tumour removal is not immediately possible. The goal is to control disease while minimising treatment-related side effects.
- Radiation therapy is considered only in specific situations where local tumour control is required and other options are insufficient.
Intermediate-risk neuroblastoma
- Combined surgery and chemotherapy form the backbone of treatment. Chemotherapy is used to shrink the tumour, making surgical removal safer and more effective, while also addressing any microscopic disease.
- Treatment intensity is carefully balanced, aiming for high cure rates while reducing long-term complications related to growth, development, and organ function.
- Radiation therapy may be incorporated selectively when residual tumour remains after surgery and chemotherapy, or when tumour location limits complete surgical removal.
High-risk neuroblastoma
- Induction therapy with multi-agent chemotherapy is used to aggressively reduce tumour burden and control disease that may have spread to other parts of the body. This phase requires close monitoring and specialised supportive care.
- Local control through surgery and targeted radiation therapy is planned once the tumour responds to chemotherapy, focusing on effective removal or control of the primary tumour site.
- Consolidation therapy involves high-dose (myeloablative) chemotherapy followed by autologous stem cell transplant, allowing higher treatment intensity while restoring bone marrow function.
- Maintenance therapy, including differentiation therapy with 13-cis retinoic acid, with or without immunotherapy, is used to reduce the risk of recurrence by targeting remaining cancer cells and supporting long-term disease control.
Throughout treatment, children are regularly assessed to evaluate response, manage side effects, and adjust therapy when required, ensuring care remains both effective and safe at every stage.
Supportive and Paediatric-Focused Care at RGCIRC
Alongside cancer-directed treatment, supportive care plays a vital role in helping children tolerate therapy, recover safely, and maintain quality of life. At RGCIRC, supportive care is integrated into every stage of neuroblastoma treatment, recognising the unique physical and emotional needs of young patients and their families.
Care for children undergoing neuroblastoma treatment includes:
- Symptom and pain management: Close monitoring to control pain, nausea, fatigue, and other treatment-related side effects, helping children remain as comfortable as possible throughout therapy
- Nutritional support: Age-appropriate and treatment-specific nutrition planning to maintain strength, support healthy growth, and aid recovery during and after intensive treatment
- Infection prevention and monitoring: Enhanced precautions and regular monitoring, particularly during chemotherapy and stem cell transplant phases when immunity may be reduced
- Psychological and emotional support: Support for anxiety, fear, and behavioural changes in children, along with counselling and guidance for parents and caregivers
- Rehabilitation and developmental support: Measures to preserve mobility, physical function, and age-appropriate development during long and intensive treatment courses
This comprehensive, child-centred approach ensures that treatment focuses not only on controlling the disease but also on the child’s overall wellbeing, helping families navigate the neuroblastoma journey with greater confidence and continuity of care.
Life After Neuroblastoma Treatment
Completion of neuroblastoma treatment marks an important milestone, but continued care remains essential. Children who have undergone treatment require structured follow-up to monitor recovery, detect any signs of recurrence early, and address potential long-term effects related to therapy.
Post-treatment care typically includes:
- Regular follow-up visits and imaging: Scheduled according to the child’s risk category and treatment history to monitor recovery and ensure ongoing disease control
- Monitoring for late effects: Assessment of growth and development, organ function, hearing, and hormonal balance, particularly in children who have received intensive therapy
- Rehabilitation and supportive therapies: Support to help children regain strength, mobility, and confidence as they gradually return to daily activities
- Psychosocial support for survivors and families: Ongoing emotional and psychological support recognising the long-term impact of cancer treatment even after therapy ends
With appropriate long-term surveillance and support, many children treated for neuroblastoma go on to lead healthy, active lives. A structured survivorship care plan helps families transition from active treatment to ongoing wellness and monitoring.
Why Choose RGCIRC for Neuroblastoma Treatment in Delhi
Neuroblastoma requires highly specialised, coordinated care delivered by teams experienced in managing rare and complex childhood cancers. At RGCIRC, neuroblastoma treatment is approached through evidence-based protocols, advanced diagnostics, and a strong focus on child- and family-centred care.
Here’s why families choose RGCIRC for neuroblastoma treatment in Delhi:
- Specialised paediatric oncology expertise: Dedicated teams experienced in treating neuroblastoma across risk categories, including high-risk and relapsed disease, using evidence-based, protocol-driven approaches tailored to each child’s clinical profile.
- Advanced diagnostic and tumour biology assessment: In-house imaging, bone marrow evaluation, molecular and cytogenetic testing, and tumour biology analysis enable accurate staging, risk classification, and treatment planning, which are critical in neuroblastoma management.
- Multidisciplinary tumour board-led care: Each case is reviewed through structured multidisciplinary discussions involving paediatric oncologists, surgeons, radiation oncologists, transplant specialists, radiologists, pathologists, and supportive care teams, ensuring coordinated decision-making at every stage.
- Comprehensive treatment capabilities for high-risk disease: RGCIRC is equipped to deliver intensive multimodal therapy, including multi-agent chemotherapy, specialised surgery, precision radiation therapy, high-dose chemotherapy with autologous stem cell transplantation, and differentiation therapy when indicated.
- Research-driven and ethically grounded oncology practice: Treatment protocols at RGCIRC are aligned with evolving global evidence and supported by advanced diagnostics, long-term outcome tracking, and institutional research initiatives. This research-oriented approach is particularly important for rare and biologically complex cancers such as neuroblastoma.
- Integrated supportive and child-focused care: Pain management, nutritional support, infection prevention, psychological counselling, rehabilitation, and developmental support are embedded into the treatment pathway, addressing the physical and emotional needs of both children and their families.
- Continuity of care from diagnosis to survivorship: Structured follow-up programmes at RGCIRC support recovery, monitor for recurrence, and manage late effects of treatment, ensuring long-term care beyond completion of therapy.
By combining paediatric oncology expertise, advanced diagnostics, research-driven treatment planning, and comprehensive supportive care, RGCIRC provides comprehensive neuroblastoma care focused not only on disease control but also on the long-term health and wellbeing of every child.
Moving Forward with Confidence
A diagnosis of neuroblastoma can be overwhelming for families, but timely, specialised care plays a critical role in improving outcomes and supporting long-term recovery. With accurate diagnosis, risk-adapted treatment, and comprehensive supportive care, many children respond well to therapy and go on to lead healthy lives. To consult a paediatric cancer specialist at RGCIRC for neuroblastoma evaluation and treatment, simply call +91-11-47022222, +91 11 27051037.
Frequently Asked Questions (FAQs)
Is neuroblastoma treatable if detected early?
Yes. Children with low- and intermediate-risk neuroblastoma often respond very well to treatment, and in selected cases, careful observation or limited therapy may be sufficient.
Is specialised neuroblastoma treatment available near me in Delhi?
Yes. Specialised cancer centres in Delhi with dedicated paediatric oncology services provide structured diagnosis, risk classification, and comprehensive neuroblastoma treatment. Rajiv Gandhi Cancer Institute & Research Centre offers specialised care for neuroblastoma through experienced paediatric oncology teams, advanced diagnostics, and multidisciplinary treatment planning.
Does RGCIRC offer paediatric oncology services?
Yes. RGCIRC provides specialised paediatric oncology services, including the diagnosis and treatment of childhood cancers such as neuroblastoma, supported by multidisciplinary teams and comprehensive supportive care.
Does RGCIRC treat high-risk neuroblastoma?
Yes. RGCIRC provides comprehensive care for both early-stage and high-risk neuroblastoma, including intensive chemotherapy, surgery, radiation therapy, stem cell transplantation, and long-term follow-up.
How long does neuroblastoma treatment usually last?
Treatment duration varies based on the risk category. Low-risk cases may require a short treatment course or observation, while high-risk neuroblastoma involves multi-stage therapy that can extend over several months.
What are the side effects of neuroblastoma treatment?
Side effects depend on the type and intensity of treatment and may include fatigue, nausea, temporary hair loss, increased infection risk, or appetite changes. Supportive care is provided to manage side effects and maintain the child’s comfort.
How can parents support a child emotionally during neuroblastoma treatment?
Emotional support, age-appropriate communication, and access to psychological counselling can help children cope better during treatment. Active family involvement is an important part of the care process.
Can neuroblastoma come back after treatment?
Recurrence is possible, particularly in high-risk neuroblastoma, which is why structured follow-up is essential. Regular monitoring allows early detection and timely management if the disease returns.
Will my child need long-term follow-up after treatment?
Yes. Long-term follow-up is important to monitor recovery, detect recurrence early, and identify any late effects of treatment.
What follow-up care is needed after neuroblastoma treatment?
Follow-up care includes regular clinical visits, imaging, and tests to monitor health, growth, development, and organ function. Follow-up plans are tailored to each child’s treatment history and risk profile.